INVENTIVA shares closed down 5.05% at €4.515, compared to €4.76 the previous day. This defensive session is part of a short-term negative trend, with a cumulative loss of 6.91% over the last seven days. Trading remained moderate with 0.25% of the capital traded, contrasting with the 1.07% rise of the CAC 40 which ended at 8,060.13 points. Despite this recent decline, INVENTIVA maintains remarkable performance over longer periods, showing a gain of 70.7% over three months and a spectacular increase of 201.4% over one year, significantly outperforming the CAC 40's 6.39% over the same period. This volatility of 15.79% over one month reflects the significant fluctuations characteristic of biotechnological stocks.
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
Almost there! Check your inbox.
A confirmation email has been sent. Click the link to confirm your subscription.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Technical analysis reveals that the stock is currently close to its support threshold at €4.39, offering limited safety margin in case of further selling pressure. The technical resistance is at €5.34, a level the stock must surpass to regain an upward momentum. The Relative Strength Index (RSI) at 58 points indicates a neutral position, neither oversold nor overbought, suggesting that today's downward movement does not yet reflect any technical excess. The MACD, a momentum indicator that measures the convergence of moving averages, displays a main line at 0.18 slightly below its signal line at 0.19, with a histogram close to zero. This configuration suggests a phase of hesitation in the trend, without a marked directional signal in the short term.
The moving averages provide a contrasting perspective on the stock's trend. The stock maintains above its 50-day moving average (€4.16) and more clearly above its 200-day moving average (€3.06), confirming the strength of the underlying trend despite recent turbulence. This positive hierarchy of moving averages testifies to the strength of the bullish movement engaged for several months. The Bollinger Bands, which frame fluctuations between €4.27 and €5.31, show that the stock is moving in the lower part of its recent volatility channel. The negative Chaikin Money Flow at -0.12 and the OBV in negative territory suggest a weakening of buyer flows, consistent with the correction observed in recent sessions.
Position de trésorerie au 30/09/2025 de 97,6 millions d’euros (plus 24,7 millions d’euros en dépôts à court terme) ; revenus de 4,5 millions d'euros sur les neuf premiers mois de 2025 principalement liés à CTTQ ; flux opérationnels consommés de - 76,3 millions d’euros et flux d'investissement de - 25 millions d’euros ; flux de financement positifs de 103,4 millions d’euros incluant le produit net de la deuxième tranche du financement structuré. Offre publique en novembre 2025 d’ADS apportant un produit net d’environ 139,3 millions d’euros et estimation d’un horizon de trésorerie jusqu’à fin T1 2027 (pouvant aller jusqu’à mi-T3 2027 si exercice intégral de la Tranche 3 pouvant apporter 116,0 millions d'euros).
Risks mentioned
Besoin de capitaux supplémentaires pour financer les opérations
Risque que la Société utilise ses ressources plus rapidement que prévu
Incertitudes et risques liés aux essais cliniques et aux autorisations réglementaires
Dépendance au succès du lanifibranor et des résultats de l'essai NATiV3
Opportunities identified
Produit net de l’offre publique en novembre 2025 d’environ 139,3 millions d’euros renforçant la trésorerie
Exercice potentiel de la Tranche 3 pouvant apporter jusqu’à 116,0 millions d'euros supplémentaires
Paiement d'étape et avoirs liés à l’accord avec CTTQ (10 M$ et 5 M$)
Résultats principaux de l’essai NATiV3 attendus au second semestre 2026
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
